Danish Cooperative Study
|
Status:
Trial complete. Results published 1/83.
Purpose:
To determine if acetylsalicylic acid (ASA) would reduce stroke frequency and mortality in patients with reversible cerebral ischemic attacks.
Design:
Cooperative, double-blind, placebo-controlled, randomized trial of 203 patients at 6 centers.
Inclusion Criteria
At least one reversible cerebral or retinal ischemic attack of less than 72 hours duration occurring within 1 month of hospital admission, < 75 years of age.
Exclusion Criteria
Severe residual symptoms from a previous stroke, bad physical condition due to other illness, history of bleeding peptic ulcer or active peptic ulcer, hypersensitivity to ASA, already taking ASA or platelet inhibiting drugs, patients referred to carotid surgery.
Patient Involvement:
Patients were randomized to receive treatment of either ASA 1000 mg daily or placebo. Follow-up visits took place every month initially and later at intervals of up to 6 months. Median follow-up period was 25 months.
Primary Outcome:
Stroke or death.
Secondary Outcome:
Recurrence of transient ischemic attack, non-fatal myocardial infarction.
Results:
No statistically significant differences were found in the occurrence of stroke or death (or any other variables) between the two groups.
Source of Information:
Stroke 1983 Jan-Feb;14(1):15-22
|
|
Web Links and Publications:
|
|
This information last updated on: 4/5/2001
|
Trials
Directories